Yarrow Bioscience (NASDAQ:YARW) Posts Quarterly Earnings Results

Yarrow Bioscience (NASDAQ:YARW) issued its quarterly earnings results on Thursday. The company reported ($2.14) earnings per share (EPS) for the quarter, Zacks reports. Yarrow Bioscience had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.

Yarrow Bioscience Stock Down 0.1%

Shares of YARW stock traded down $0.05 during mid-day trading on Thursday, reaching $42.72. The stock had a trading volume of 13,552 shares, compared to its average volume of 11,479. The stock has a market cap of $28.54 million, a P/E ratio of -2.25 and a beta of 1.96. Yarrow Bioscience has a 12-month low of $14.02 and a 12-month high of $46.95.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on YARW shares. BTIG Research assumed coverage on Yarrow Bioscience in a research report on Monday, August 3rd. They set a “buy” rating and a $58.00 target price on the stock. TD Cowen initiated coverage on Yarrow Bioscience in a report on Tuesday, July 28th. They issued a “buy” rating for the company. Two analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $58.00.

Yarrow Bioscience Company Profile

VYNE Therapeutics Inc, a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2.